INTRODUCTION
Calcium homeostasis and activation in many cells rely on a Ca 2+ signal originated via a mechanism known as store-operated calcium entry (SOCE) (1) , which in the case of T lymphocytes is of particular relevance and is triggered following antigen binding to the T-cell receptor and endoplasmic reticulum (ER) Ca 2+ depletion (2) . The major Ca 2+ sensor in the ER, the stromal interaction molecule 1 (STIM1) (3, 4) , activates plasma membrane-localized Orai channels (5), ultimately giving rise to what is known as the Ca 2+ release-activated Ca 2+ current (I CRAC ) (6) . Similarly, activation of other immune cells, such as mast cells or dendritic cells, also depends on the influx of Ca 2+ into the cytosol (reviewed in 7). Ca 2+ signals generated by Orai channels promote the translocation of several transcription factors to the nucleus, the nuclear factor of activated T cells (NFAT) particularly being relevant to lymphocyte physiology (8) . Activation and translocation of NFAT, in turn, trigger the transcription of different genes related to T-cell activation such as interleukin 2 (IL-2) (9,10). Several proteins have been recently reported to modulate CRAC channel-mediated Ca 2+ signals at different levels. CRACR2A is a cytosolic protein that stabilizes the STIMOrai interaction in a Ca 2+ -dependent manner, thereby enhancing SOCE (11) . Two other proteins, Golli (12, 13) and stanniocalcin 2 (14) , interact with STIM1 reducing SOCE. CRAC channels are also regulated by a negative feedback mechanism known as calcium-dependent inactivation (CDI) due to the accumulation of Ca 2+ in the immediate vicinity of the channels (15) (16) (17) . Two proteins have been described to participate in this process. Interaction of calmodulin with both STIM1 and Orai1 triggers rapid CDI of the CRAC channel (18) , while the ER protein SARAF associates with STIM to facilitate slow CDI (19) .
The calcium buffering system of the cell, which includes Ca 2+ uptake into the ER and mitochondria as well as extrusion via the plasma membrane, also modulates I CRAC current by preventing CDI (20 -25) . In this context, it is important to point out that ER and mitochondrial shaping of calcium signals may be functionally connected at the mitochondrialassociated membranes (MAMs) (26) which are the zones of close contact between these organelles. Several proteins act as tethering sites at MAMs, including calcium transporters such as the sarco-endoplasmic calcium ATPase pump (SERCA) and inositol trisphosphate receptors in the ER membrane and the voltage-dependent anion channel in the outer mitochondrial membrane (26, 27) .
The ER-resident transmembrane protein orosomucoid like 3 (ORMDL3) (28) regulates ER calcium homeostasis via inhibition of SERCA2b (29) and modulates the unfolded protein response (29, 30) . ORMDL3 is coded by the ORMDL3 gene, whose expression has been reported in the cells that participate in the inflammatory response such as T lymphocytes (28, 31) . Single nucleotide polymorphisms located in the regulatory regions modify ORMDL3 expression levels and have been associated with different immune-mediated inflammatory diseases such as asthma, ulcerative colitis, type 1 diabetes and Crohn's disease (30) (31) (32) (33) . All these diseases also share a deregulation of T-lymphocyte activation (33) (34) (35) (36) .
Given the findings that (1) ORMDL3 is associated with several inflammatory and autoimmune diseases; (2) ORMDL3 regulates ER Ca 2+ homeostasis; (3) Ca 2+ influx is essential for triggering T-lymphocyte activation and (4) T-lymphocyte activation is a key step in the proinflammatory response; we postulate that ORMDL3 expression might be affecting SOCE and T-lymphocyte activation.
RESULTS

ORMDL3 alters cytoplasmic calcium levels and ER Ca 21 release in lymphocytes
To elucidate the role of ORMDL3 in lymphocyte physiology and the link between genetic associations of the ORMDL3 gene with autoimmune and/or inflammatory diseases, we have investigated the impact of ORMDL3 on Ca 2+ homeostasis and activation of Jurkat T cells.
We first reassessed whether the effect of ORMDL3 overexpression on the cytoplasmic and ER Ca 2+ levels in Jurkat T cells was similar to what was previously reported for HEK293 cells (29) . ORMDL3 overexpression in Jurkat T cells increased cytoplasmic Ca 2+ (Fig. 1A) and decreased the ER Ca 2+ release triggered by the SERCA inhibitor cyclopiazonic acid (CPA, 30 mM), which mainly reflects the amount of Ca 2+ stored in the ER (Fig. 1B and C) . Similar results were obtained with the siRNA-mediated knockdown of the SERCA pump (Fig. 1A, D and E) , thereby confirming our previous results that proposed the interaction of ORMDL3 with SERCA causing the inhibition of the pump (29) . ORMDL3 knockdown with siRNA increased ER Ca 2+ release ( Fig. 1D  and E ) with no apparent effect on basal cytoplasmic Ca 2+ (Fig. 1A) .
ORMDL3 regulates store-operated calcium entry
Ca
2+ signaling is of paramount importance in immune system physiology. Indeed, activation of T cells depends on a sustained increase in cytosolic Ca 2+ concentration through SOCE (7, 8) . We evaluated SOCE in transiently transfected Jurkat T cells incubated with anti-CD3 antibody and stimulated with a secondary antibody that promotes TCR aggregation and SOCE (Fig. 2) . ORMDL3 overexpression reduced Ca 2+ entry, seen upon addition of Ca 2+ to the extracellular medium, compared with its control ORMDL3-△1-16 ( Fig. 2A and B) , an ORMDL3 mutant lacking the cytosolic Nterminal domain. This N-terminal sequence is not present in the yeast orthologs, Orms (Supplementary Material, Fig. S1A and B) . When expressed in Jurkat T lymphocytes and HEK293 cells, ORMDL3-△1-16 showed the same characteristics as GFP transfected control cells (Supplementary Material, Fig. S1C and D) . Thereafter, this mutant was used as a control in overexpression experiments. On the other hand, siRNA-mediated knockdown of ORMDL3 increased SOCE after CD3 stimulation ( Fig. 2C and D (37) (38) (39) . We analyzed endogenous whole-cell CRAC current (I CRAC ) in Jurkat T cells transiently transfected with ORMDL3-WT or ORMDL3-△1-16 ( Fig. 3A -C) . In order to passively deplete ER stores and activate I CRAC , we included the Ca 2+ chelator EGTA (10 mM) in the internal pipette solution (6) . Our results show that compared with the cells overexpressing ORMDL3-△1-16, the cells overexpressing ORMDL3-WT presented a decrease in current density and a delay in the development of the current (Fig. 3A -C) . Downregulation of ORMDL3 expression with siRNA provoked an increase in current density and a faster development of I CRAC compared with control siRNA (Fig. 3D -F) .
Yeast ORMDL3 orthologs, Orms, are implicated in sphingolipid metabolism (40, 41) . Orms inhibit serin palmitoyltranferase (SPT) and block the sphingolipid biosynthetic pathway, although at present it is not known whether a similar function is preserved in mammalian ORMDLs. Myriocin is a specific inhibitor of the SPT that has been previously used as a pharmacological tool to mimic Orms function (40, 41) . However, treatment with 10 mg/ml myriocin for 24 h did not affect the current density or the delay time of I CRAC (Supplementary Material, Fig. S2 ).
ORMDL3 modifies lymphocyte activation
A sustained Ca 2+ concentration increase in the cytoplasm promotes NFAT dephosphorylation and its nuclear translocation (8) . We tested NFAT nuclear translocation by confocal microscopy in resting and activated Jurkat T lymphocytes. To monitor NFAT location, we overexpressed a NFAT1 -GFP fusion protein and quantified the NFAT1-GFP signal present in the nucleus at 30 and 6 h after activation with
520
Human Molecular Genetics, 2013, Vol. 22, No. 3 thapsigargine (TG, 1 mM) plus phorbol 12-myristate 13-acetate (PMA, 20 nM) ( Fig. 4A and B) . Compared with ORMDL3-△1-16, overexpression of ORMDL3-WT reduced the translocation of NFAT to the nucleus in activated cells (Fig. 4A) , while siRNA-mediated downregulation of ORMDL3 was associated with higher NFAT translocation 6 h after activation (Fig. 4B) . However, no difference in NFAT translocation was observed under these conditions at 30 min. These results are in agreement with previous data showing that reduction of as much as 50% of the SOCE response mainly impacts on the late phase of NFAT translocation (42) .
One of the earliest genes transcribed following the activation program in T cells and used as an early marker of activation is IL-2. We tested IL-2-positive cells using a flow cytometry-based intracellular staining technique in Jurkat T cells in which ORMDL3 was overexpressed or downregulated ( Fig. 4C and D) . The cells were activated as described above 
ORMDL3 localizes near STIM -Orai puncta
The trigger for the opening of CRAC channels involves the interaction between STIM proteins located in the ER and Orai proteins present in the plasma membrane (43) . We analyzed whether ORMDL3 colocalized with STIM1 and Orai1. Besides, the differences in I CRAC and SOCE observed following alteration of ORMDL3 expression levels were not due to differences in the expression of STIM1 or Orai1, which remained unmodified (Supplementary Material, Fig. S4 ).
ORMDL3 increases I CRAC calcium-dependent inactivation
CRAC channel activity is negatively regulated by cytosolic Ca 2+ levels in both a fast and slow time scale (15) (16) (17) , a process that is prevented with strong buffering of the intracellular Ca 2+ . In order to explore whether the mechanism behind ORMDL3 modulation of SOCE was related to CDI of CRAC channels, we recorded endogenous whole-cell I CRAC using the fast Ca 2+ chelator BAPTA (as slow CDI is not fully prevented in the presence of 10 mM EGTA (44, 45) ) in the internal solution of the patch pipette. In the presence of BAPTA, ORMDL3 overexpression did not produce any effect on I CRAC development or the current density ( Fig. 5A and B ). This result suggested that ORMDL3 affects I CRAC CDI. To further explore Fig. 5C and E ). An addition of high concentrations of the slow Ca 2+ chelator EGTA (20 mM) to the pipette solution abolished the ORMDL3-induced slow CDI of I CRAC (Fig. 5D and F) . Together these experiments suggested an ORMDL3-dependent modulation of I CRAC CDI.
ORMDL3 binds to and inhibits the SERCA pump promoting cytosolic calcium accumulation (29) , although several pieces of evidence argue against the ORMDL3-dependent inhibition of SERCA as the cause of the increased I CRAC CDI observed in the cells overexpressing ORMDL3. First, the ORMDL3-dependent effect on I CRAC slow CDI appeared in the presence of the irreversible SERCA inhibitor TG (Fig. 5C ). Second, we obtained a similar reduction in SOCE response when we applied CPA (Supplementary Material, Fig. S5A ) or anti-CD3 ( Fig. 2A) . Third, siRNA-mediated knockdown of SERCA reduced the CPA-induced ER Ca 
ORMDL3 reduces mitochondrial calcium uptake
In an attempt to identify the mechanism of ORMDL3-dependent modulation of SOCE, we focused our attention on mitochondria as Ca 2+ influx into these organelles modulates I CRAC CDI and SOCE (23, 24, 46) .
Punctual colocalization of ORMDL3 with mitotracker was detected in Jurkat cells (Supplementary Material, Fig. S6A ), which was similar to that described for ER proteins present at the ER -mitochondria junctions (27) . Application of antimycin A and oligomycin (which both depolarize mitochondrial potential and thereby impair Ca 2+ uptake into the mitochondria (47)) reduced SOCE in ORMDL3-D1-16 expressing cells to the level seen in ORMDL3-WT expressing cells (Fig. 6A, left) . On the other hand, kaempferol, an activator of the mitochondrial Ca 2+ uniporter (48) , reverted the ORMDL3-induced SOCE phenotype back to control (ORMDL3-D1-16) levels (Fig. 6A,  middle) . Together, these experiments showed that the effect of ORMDL3 overexpression on SOCE was mimicked by pharmacological manipulation of mitochondrial Ca 2+ influx (Fig. 6A  right) . Next, we evaluated whether ORMDL3 could affect Ca 2+ influx into the mitochondria using a mitochondrially targeted GFP-based ratiometric Pericam Ca 2+ sensor (mtPericamR) (49) 2+ influx into the mitochondria of ORMDL3-expressing cells was lower than in ORMDL3-D1-16 expressing cells (Fig. 6B ), pointing to a deficient mitochondrial Ca 2+ influx as the primary cause of increased I CRAC CDI and reduced SOCE. Opposite results of mitochondrial uptake were obtained downregulating ORMDL3 with siRNAs (Fig. 6C) . Similar changes in mitochondrial [Ca 2+ ] were obtained using CPA in non-permeabilized cells or using the calcium dye rhod-5N (Supplementary Material, Fig. S6 ).
Finally, considering that removal of the N-terminus renders ORMDL3 unable to regulate SOCE, we tested the effect of (Fig. 6D and E) . Altogether, our results indicated that ORMDL3 affects mitochondrial Ca 2+ influx and the Ca 2+ buffering capacity of the cell, thereby affecting the CDI of CRAC channels.
DISCUSSION
The association of the ORMDL3 gene with several proinflammatory and autoimmune diseases suggests that ORMDL3 protein may play an important role in the immune system physiology. Cells of the immune system express ORMDL3 (28,31) and increased expression of ORMDL3 has been associated with higher risk of childhood asthma (31) . We have previously shown that the product of this gene is an ER protein that participates in ER-mediated Ca 2+ homeostasis and stress responses (29) , thereby providing a link between asthma, ORMDL3 and dysregulation of Ca 2+ homeostasis. Additional support for the hypothesis that genetic variants with impact in Ca 2+ homeostasis are relevant to asthma pathophysiology comes from an association study of transient receptor potential cationic channels with the severity of childhood asthma (51)(reviewed by 52). In the present study, we have carried out a deeper evaluation of ORMDL3 function focusing on the impact of ORMDL3 on SOCE and lymphocyte activation. Our results show that ORMDL3 modulates SOCE and lymphocyte activation, an effect that may sum to the previously described effect on ER Ca 2+ imbalance and stress (29) . We have shown that overexpression of ORMDL3 decreases SOCE and T-cell activation. Impaired Ca 2+ signaling in T cells has been linked to inherited immunodeficiency diseases (37) but evidences also exist linking deficient T-cell Ca 2+ signaling to proinflammatory conditions. Mice lacking both STIM1 and STIM2 present an impaired SOCE but show splenomegaly, lymphadenopathy and leukocyte infiltration in several tissues, including lungs, due to anomalous regulatory T-lymphocyte development (42, 53) . Similarly, ablation of the signaling cascade downstream SOCE (e.g. NFAT (54)) or mutations in the upstream signaling elements (in the linker for activation of T cells (LAT) that prevent PLCg activation (55, 56) ) resulted in mice presenting lymphoproliferative and autoimmune phenotypes. In summary, it is possible that disruption of the fine tuning of the SOCE-NFAT pathway determines T-cell dysfunction, which may be expressed at the individual level as proinflammatory or immunodeficient conditions. It is not yet known how ORMDL3 may be affecting the immune system in animal models but the fact that it modulates lymphocyte activation suggests that it may also have an impact on the overall immune system response.
Our results demonstrate that ORMDL3 modifies SOCE response by altering the slow CDI of the CRAC channel, an effect that requires the N-terminus of the protein, which is sufficient to induce modulation of the SOCE. ORMDL3 binds to and inhibits the SERCA pump (29) reducing the ER calcium content. Both, SERCA (21) and ORMDL3 (this study), localize close to the STIM-Orai interaction sites in activated lymphocytes. However, ORMDL3-mediated modulation of I CRAC and SOCE is independent of SERCA activity since these effects are observed in the presence of SERCA inhibitors.
In our search for factors that may explain the ORMDL3-mediated differences in I CRAC and SOCE, we focused on the mitochondria as these organelles are found in close proximity to both the ER and the plasma membrane (26, 57) and are capable of modulating Ca 2+ signals (58, 59) . Through their ability to take up cytoplasmic Ca 2+ , mitochondria exert a dual effect on SOCE. Mitochondrial competition for the Ca 2+ used by SERCA to refill the ER initially enhances I CRAC activation (accelerating I CRAC development), while in a slower time scale reduces inactivation of CRAC channels (23, 46, 60, 61) . Besides that, mitochondria migrate near Orai channels during SOCE activation and formation of an immunological synapse, further favoring the removal of calcium from the channel vicinity and preventing CDI (62, 63) . Mitochondria has also been recently proposed to exert a permissive role in STIM1 trafficking (64) .
The fact that mitochondrial Ca 2+ uptake is impaired in ORMDL3 overexpressing cells and enhanced by knocking down ORMDL3 with siRNA may explain the effect of ORMDL3 on I CRAC and SOCE. Several pieces of evidence support this conclusion. First, depolarization of the mitochondrial potential, preventing mitochondrial calcium buffering capacity, mimics the ORMDL3 effect on SOCE, while favoring mitochondrial Ca 2+ import upon application of kaempferol reverts the effect of ORMDL3 on SOCE. Second, the changes in I CRAC development vary according to a reduced mitochondrial Ca 2+ influx (increased delay in ORMDL3 overexpressing cells) or increased mitochondrial Ca 2+ influx (reduced delay in ORMDL3 siRNA-treated cells). Third, augmented I CRAC CDI in ORMDL3 expressing cells is also consistent with a reduced mitochondrial Ca 2+ influx. The fact that high concentration of EGTA (and lower concentration of BAPTA) reduced the ORMDL3-induced CDI of I CRAC along with the involvement of the mitochondria in this process suggests that ORMDL3 affects I CRAC slow CDI. Fourth, the ORMDL3-mediated changes in mitochondrial Ca 2+ influx are not secondary to alterations in SOCE as similar changes were obtained in permeabilized cells exposed to the same [Ca 2+ ]. Fifth, we observed punctual colocalization of ORMDL3 with mitochondria, similar to that described for the physical interacting spots between ER and mitochondria called MAMs (26) . We have not evaluated whether ORMDL3 may be also affecting the metabolic activity and the ATP production at the mitochondria, which in turn may be affecting the SERCA pump activity and ER calcium refilling (65) .
Yeast orthologs of ORMDL3 (Orms) participate in sphingolipid metabolism and stress pathways (40, 41) . However, in our hands myriocin did not affect I CRAC in Jurkat T cells. Moreover, the N-terminus region of Orms, essential for its activity regulation (66) (67) (68) , is not conserved in mammals. Nevertheless, our experiments with the ORMDL3-△1-16 mutant and the overexpression of the N-terminus alone demonstrate that the residues present in the mammalian N-terminus are essential for the ORMDL3 activity.
In conclusion, we have shown that ORMDL3 expression levels modify T-cell calcium signaling and lymphocyte activation following the alteration of the mitochondrial Ca 2+ influx and I CRAC CDI. Our data point to ORMDL3 as the first ER-based protein modulating Ca 2+ transport into the mitochondria and places it at an important position in the control of Ca 2+ transport into the major intracellular stores. Moreover, our data offer a pathophysiological mechanism, the regulation of SOCE and lymphocyte activation, by which ORMDL3 may be participating in those immune and/or inflammatory diseases showing altered levels of ORMDL3 expression.
MATERIALS AND METHODS
Reagents, plasmids and cell culture
Jurkat T cells were maintained in Roswell Park Memorial Institute medium plus 10% fetal bovine serum (FBS) and HEK293 cells were cultured in Dulbecco's modified Eagle's medium plus 10% FBS. Transient transfection of Jurkat T cells and HEK293 cells was carried out using TransIT-Jurkat transfection reagent (Mirus Bio Corporation) and ExGen500 (Fermentas MBI), respectively.
Activation of Jurkat T cells was carried out with phorbol-12-myristate-13-acetate (PMA, 20 nM) and TG (1 mM) for 6 h. For those experiments using myriocin (10 mg/ml) to inhibit the serine palmitoyltranferase enzyme, the cells were treated for 24 h. All chemicals unless otherwise indicated were obtained from Sigma.
ORMDL3 amino terminal deletion (ORMDL3-D1-16) was generated by PCR and cloned into pCDNA3 vector. The sequence of the ORMDL3 N-terminus was cloned in a pcmv-myc expressing vector (ORMDL3-Nter) producing the following fusion peptide MASMQKLISEEDLLMAMEAR-ILNVGTAHSEVNPNTRVMNSR. NFAT1 expression vector was a kind gift from Dr J. Aramburu (Universitat Pompeu Fabra), pmaxSTIM1-CFP and pmaxOrai1-YFP were a gentle gift from Dr Samelson LE (National Cancer Institute, (29) . SERCA siRNA was purchased from Invitrogen. These siRNAs were transfected using Lipofectamin 2000 (Invitrogen).
Measurement of intracellular [Ca
]
A cytosolic Ca 2+ signal was determined in cells loaded with 4.5 mM fura-2 . AM (20 min) as previously described (69) . Cytosolic [Ca 2+ ] increases are presented as the ratio of emitted fluorescence (510 nm) after excitation at 340 and 380 nm, relative to the ratio measured prior to cell stimulation (fura-2 ratio 340/380).
Mitochondrial calcium levels were obtained in cells loaded for 15 min at 378C with 5 mM rhodamine-5N-AM (50) or transfected with mtPericamR (49) . Calcium increases in rhodamineloaded cells are presented as an increase in emitted fluorescence (590 nm) after excitation (561 nm). Ratiometric-pericam-mt imaging was obtained by excitation at 410 and 488 nm and emission at 520 nm in a Leica TCS SP5 confocal microscope with a 40× Oil objective and analyzed using ImageJ software. All experiments were carried out at room temperature and the cells were bathed in a solution containing (in mM): 140 NaCl, 5 KCl, 1.2 CaCl 2 , 0.5 MgCl 2 , 5 glucose, 10 HEPES; 300 mosmol/l, pH 7.4 with Tris). Ca 2+ -free solutions were obtained by replacing CaCl 2 with equal amounts of MgCl 2 plus 0.5 mM EGTA and 10 mM Digitonin when indicated.
Store depletion was achieved in Jurkat T cells using anti-CD3 hybridoma SN and crosslinked with a secondary anti-Fc-specific mouse antibody (Sigma m2650 1:100). CPA was used at 30 mM and 10 mM in Jurkat and HEK293 cells, respectively.
NFAT nuclear translocation assay and immunostaining
Cells were transfected with NFAT1-GFP plus ORMDL3, ORMDL3-D1-16 or with siRNAs. After transfection, the cells were seeded on poly-L-lysine pretreated coverslips at the indicated time lapses. The cells were fixed with 4% paraformaldehyde for 15 min and nuclear staining was performed for 10 min with TO-PRO3. NFAT translocation was calculated as the ratio of nuclear NFAT-GFP signal to total NFAT1-GFP.
Colocalization experiments were performed in the cells transfected with STIM-CFP and Orai-YFP. After fixation, immunostaining for ORMDL3 was done using a commercial anti-ORMDL3 antibody (1:100, Abgent). Briefly, the cells were permeabilized for 10 min with 0.1% Triton in phosphate buffered saline (PBS). Blocking and antibody incubating solution contained 2% FBS, 1% BSA and 0.5% Triton in PBS. Images were acquired using an inverted Leica SP2 confocal microscope with a 40× 1.32 Oil Ph3 CS objective and analyzed using ImageJ software.
IL2 intracellular staining
Cells transfected with ORMDL3-WT, ORMDL3-D1-16 or siRNAs plus GFP were washed twice with ice-cold PBS solution and fixed with paraformaldehyde at 4%. The cells were then permeabilized and blocked with 2% BSA plus 0.5% saponin (in PBS). Intracellular IL-2 staining was carried out using PE rat anti-human IL-2 (BD Pharmagen). LSRII (Beckton Dickinson) 488 laser was used to gate transfected cells and 575/25 filter to evaluate IL2 (PE)-positive cells.
Electrophysiology
Patch-clamp experiments were performed in the whole-cell configuration with fire-polished patch pipettes (3 to 4 MV). Pipette and cell capacitance were electronically compensated before each voltage ramp with an EPC-10 patch-clamp amplifier controlled by Patchmaster software (HEKA). Membrane currents were filtered at 2.9 kHz and digitized at a sampling rate of 10 kHz. Whole-cell currents were elicited by 50 ms voltage ramps from 2100 (2120 in CDI experiments) to +100 mV from a holding potential of 0 mV. All currents were normalized by cell capacitance. For leak current correction, the ramp current before CRAC activation was subtracted. Two methods were used to trigger I CRAC . Passive depletion with pipettes filled with a solution containing (in mM): 140 cesium aspartate, 10 NaCl, 5 MgCl 2 , 10 EGTA (replaced by BAPTA in BAPTA experiment) and 10 HEPES (pH 7.2 with CsOH). The external solution contained (in mM): 155 NaCl, 4.5 KCl, 10 CaCl 2 , 2 MgCl 2 , 10 glucose, and 5 HEPES (pH 7.4 with NaOH). For CDI, pipette internal solution contained (in mM): 140 cesium aspartate, 2 MgCl 2 , 0.66 CaCl 2 , 1.2 EGTA, 10 HEPES (pH 7.2 with CsOH). To evaluate CDI of I CRAC , the cells were seeded in 0 Ca 2+ external solution containing (in mM): 135 NaCl, 4.5 KCl, 3 MgCl 2 , 0.5 EGTA, 10 glucose, 5 HEPES (pH 7.4 with NaOH). After obtaining the whole-cell configuration, the cells were incubated for 3 min in 0 Ca 2+ external solution + 1 mM TG to completely deplete internal calcium stores and then switch to a solution containing 20 mM Ca
2+
. All experiments were carried out at room temperature. The calculation of I CRAC delay was carried out using the plateau function followed by one phase association of the Graph Pad Prism 5 software.
Statistics
All data were expressed as means + SEM. Statistical analysis was performed using Student's t-test or one-way analysis of variance using SigmaPlot or OriginPro software. Bonferroni's test was used for post-hoc comparison of the mean values. The criterion for a significant difference was a final value of P , 0.05.
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